Protecting joint health

ELOCTA® protection from bleeds - key to being able to live a liberated life1

 

A median overall ABR of 0.7 and median joint AsBR of 0.0 were achieved with ELOCTA individualised prophylaxis in the ASPIRE extension trial (final data cut analysis)*,†,1

Data
Data
Data

Adapted from Oldenburg 2019.1

ELOCTA® can offer long-term protection against bleeding with the potential to provide the reassurance patients may desire for a fresh perspective on life1

ABR, annualised bleeding rate; AsBR, annualised spontaneous bleeding rate.

*ASPIRE was a phase 3 extension trial investigating the long-term efficacy and safety of ELOCTA in subjects completing A-LONG and Kids A-LONG.

n=36.1

Presented as median (interquartile range).1

Reference

1. Oldenburg J, Pasi J, Pabinger I, Nolan B, Kulkarni R, Blanchette V, et al. Improvements in joint health during long-term use of recombinant factor VIII Fc fusion protein prophylaxis in subjects with haemophilia A. Poster presented at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders, 6–8 February 2019, Prague, Czech Republic. P158.

Data

Prevention of joint damage is an important aspect of successful long-term treatment, and ELOCTA® can resolve target joints to help patients live a life beyond haemophilia1

*Patients with ≥1 target joint (major joint with ≥3 bleeding episodes in a 6-month period) at parent study entry with available pre-parent study data and on-study data were evaluated. 99.6% of evaluable target joints in A-LONG subjects were resolved. A target joint was considered clinically resolved if there were ≤2 spontaneous bleeding episodes in the target joint during a consecutive 12-month period.1

Reference

1. Oldenburg J, Pasi J, Pabinger I, Nolan B, Kulkarni R, Blanchette V, et al. Improvements in joint health during long-term use of recombinant factor VIII Fc fusion protein prophylaxis in subjects with haemophilia A. Poster presented at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders, 6–8 February 2019, Prague, Czech Republic. P158.

Improvements in mHJHS/HJHS were observed in subjects of all age groups receiving long-term rFVIIIFc prophylaxis over a median follow-up of 3.7 years1

  • Mean change in mHJHS of –5.0 from A-LONG baseline to ASPIRE Year 41
Data

Adapted from Oldenburg et al. EAHAD 2019 Poster P158.1

ELOCTA®, the first extended half-life rFVIII replacement to show long-term continuous improvement in joint health,1,2 which can give patients a fresh perspective on life

mHJHS, modified haemophilia joint health score; rFVIII, recombinant Factor VIII; SD, standard deviation of the mean.

*Number of subjects listed were those who were always on prophylaxis and had baseline mHJHS from A-LONG and at least one assessment in ASPIRE at a major assessment visit; dashed line indicates variable follow-up time between A-LONG to ASPIRE baseline, median: 8.3 months.

References

1. Oldenburg J, Pasi J, Pabinger I, Nolan B, Kulkarni R, Blanchette V, et al. Improvements in joint health during long-term use of recombinant factor VIII Fc fusion protein prophylaxis in subjects with haemophilia A. Poster presented at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders, 6–8 February 2019, Prague, Czech Republic. P158.

2. Oldenburg J, Kulkarni R, Srivastava A, Mahlangu JN, Tsao E, Winding B. Longitudinal Modified Hemophilia Joint Health Scores (mHJHS) in Children, Adolescents, and Adults with Severe Hemophilia A with Long-term rFVIIIFc Prophylaxis. Abstract presented at the XXVI International Society on Thrombosis and Haemostasis (ISTH) Congress; 2017 Jul 8–13; Berlin, Germany. PB946.

Protecting joint health

ELOCTA® protection from bleeds - key to being able to live a liberated life1

 

A median overall ABR of 0.7 and median joint AsBR of 0.0 were achieved with ELOCTA individualised prophylaxis in the ASPIRE extension trial (final data cut analysis)*,†,1

Data
Data
Data

Adapted from Oldenburg 2019.1

ELOCTA® can offer long-term protection against bleeding with the potential to provide the reassurance patients may desire for a fresh perspective on life1

ABR, annualised bleeding rate; AsBR, annualised spontaneous bleeding rate.

*ASPIRE was a phase 3 extension trial investigating the long-term efficacy and safety of ELOCTA in subjects completing A-LONG and Kids A-LONG.

n=36.1

Presented as median (interquartile range).1

Reference

1. Oldenburg J, Pasi J, Pabinger I, Nolan B, Kulkarni R, Blanchette V, et al. Improvements in joint health during long-term use of recombinant factor VIII Fc fusion protein prophylaxis in subjects with haemophilia A. Poster presented at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders, 6–8 February 2019, Prague, Czech Republic. P158.

Data

Prevention of joint damage is an important aspect of successful long-term treatment, and ELOCTA® can resolve target joints to help patients live a life beyond haemophilia1

*Patients with ≥1 target joint (major joint with ≥3 bleeding episodes in a 6-month period) at parent study entry with available pre-parent study data and on-study data were evaluated. 99.6% of evaluable target joints in A-LONG subjects were resolved. A target joint was considered clinically resolved if there were ≤2 spontaneous bleeding episodes in the target joint during a consecutive 12-month period.1

Reference

1. Oldenburg J, Pasi J, Pabinger I, Nolan B, Kulkarni R, Blanchette V, et al. Improvements in joint health during long-term use of recombinant factor VIII Fc fusion protein prophylaxis in subjects with haemophilia A. Poster presented at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders, 6–8 February 2019, Prague, Czech Republic. P158.

Improvements in mHJHS/HJHS were observed in subjects of all age groups receiving long-term rFVIIIFc prophylaxis over a median follow-up of 3.7 years1

  • Mean change in mHJHS of –5.0 from A-LONG baseline to ASPIRE Year 41
Data

Adapted from Oldenburg et al. EAHAD 2019 Poster P158.1

ELOCTA®, the first extended half-life rFVIII replacement to show long-term continuous improvement in joint health,1,2 which can give patients a fresh perspective on life

mHJHS, modified haemophilia joint health score; rFVIII, recombinant Factor VIII; SD, standard deviation of the mean.

*Number of subjects listed were those who were always on prophylaxis and had baseline mHJHS from A-LONG and at least one assessment in ASPIRE at a major assessment visit; dashed line indicates variable follow-up time between A-LONG to ASPIRE baseline, median: 8.3 months.

References

1. Oldenburg J, Pasi J, Pabinger I, Nolan B, Kulkarni R, Blanchette V, et al. Improvements in joint health during long-term use of recombinant factor VIII Fc fusion protein prophylaxis in subjects with haemophilia A. Poster presented at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders, 6–8 February 2019, Prague, Czech Republic. P158.

2. Oldenburg J, Kulkarni R, Srivastava A, Mahlangu JN, Tsao E, Winding B. Longitudinal Modified Hemophilia Joint Health Scores (mHJHS) in Children, Adolescents, and Adults with Severe Hemophilia A with Long-term rFVIIIFc Prophylaxis. Abstract presented at the XXVI International Society on Thrombosis and Haemostasis (ISTH) Congress; 2017 Jul 8–13; Berlin, Germany. PB946.